

Company Number: 609278

Seafeld Life Sciences Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 July 2025

Seafield Life Sciences Limited
CONTENTS

	Page
Directors and Other Information	3
Balance Sheet	4 - 5
Notes to the Financial Statements	6 - 8

Seafield Life Sciences Limited

DIRECTORS AND OTHER INFORMATION

Directors	Michael Mulvihill Brian Mulvihill
Company Secretary	Michael Mulvihill
Company Number	609278
Registered Office and Business Address	54 Dunluce Road, Clontarf Dublin D03 P5C2 Ireland
Accountants	Icon Accounting Chartered Certified Accountants Columba House Airside Swords Dublin Ireland
Bankers	Allied Irish Banks, p.l.c. O'Connell Street Clonmel Tipperary Ireland

Seafield Life Sciences Limited

BALANCE SHEET

as at 31 July 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	5	<u>1,428</u>	<u>1,714</u>
Current Assets			
Debtors	6	100	5,188
Cash at bank and in hand		<u>4,757</u>	<u>1,126</u>
		<u>4,857</u>	<u>6,314</u>
Creditors: amounts falling due within one year	7	<u>(22,403)</u>	<u>(6,214)</u>
Net Current (Liabilities)/Assets		<u>(17,546)</u>	<u>100</u>
Total Assets less Current Liabilities		<u><u>(16,118)</u></u>	<u><u>1,814</u></u>
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings	8	<u>(16,218)</u>	<u>1,714</u>
Shareholders' (Deficit)/Funds		<u><u>(16,118)</u></u>	<u><u>1,814</u></u>

Seafield Life Sciences Limited

BALANCE SHEET

as at 31 July 2025

We as Directors of Seafield Life Sciences Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the board on 25 September 2025 and signed on its behalf by:

Michael Mulvihill
Director

Brian Mulvihill
Director

Seafield Life Sciences Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

1. General Information

Seafield Life Sciences Limited is a company limited by shares incorporated in Ireland. The registered office of the company is 54 Dunluce Road,, Clontarf, Dublin, D03 P5C2, Ireland which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 July 2025 have been prepared on the going concern basis and in accordance with FRS 105 "The Financial Reporting Standard for Micro-Entities applicable in the UK and Republic of Ireland" (FRS 105).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Accounting Convention

The financial statements are prepared under the historical cost convention.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.50% Straight line
Motor vehicles	-	20% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Seafield Life Sciences Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund.

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Transactions, during the year, which are denominated in foreign currencies are translated at the rates of exchange ruling at the date of the transaction. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating (loss)/profit	2025	2024
	€	€
Operating (loss)/profit is stated after charging:		
Depreciation of tangible assets	286	286
	<u> </u>	<u> </u>

4. Employees

The average monthly number of employees, including directors, during the financial year was 1, (2024 - 1).

	2025	2024
	Number	Number
Consultants	1	1
	<u> </u>	<u> </u>

5. Tangible assets

	Fixtures, fittings and equipment	Motor vehicles	Total
	€	€	€
Cost			
At 1 August 2024	4,867	36,179	41,046
	<u> </u>	<u> </u>	<u> </u>
At 31 July 2025	4,867	36,179	41,046
	<u> </u>	<u> </u>	<u> </u>
Depreciation			
At 1 August 2024	3,153	36,179	39,332
Charge for the financial year	286	-	286
	<u> </u>	<u> </u>	<u> </u>
At 31 July 2025	3,439	36,179	39,618
	<u> </u>	<u> </u>	<u> </u>
Net book value			
At 31 July 2025	1,428	-	1,428
	<u> </u>	<u> </u>	<u> </u>
At 31 July 2024	1,714	-	1,714
	<u> </u>	<u> </u>	<u> </u>

Seafield Life Sciences Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 July 2025

6. Debtors	2025	2024
	€	€
Trade debtors	-	4,980
Taxation	-	108
Called up share capital not paid	100	100
	<u>100</u>	<u>5,188</u>
	<u><u>100</u></u>	<u><u>5,188</u></u>
7. Creditors	2025	2024
Amounts falling due within one year	€	€
Amounts owed to credit institutions	9,990	-
Trade creditors	240	240
Taxation	12,132	5,257
Other creditors	41	53
Accruals	-	664
	<u>22,403</u>	<u>6,214</u>
	<u><u>22,403</u></u>	<u><u>6,214</u></u>
8. Profit and loss account	2025	2024
	€	€
At 1 August 2024	1,714	(445)
(Loss)/profit for the financial year	(17,932)	2,159
At 31 July 2025	<u>(16,218)</u>	<u>1,714</u>
	<u><u>(16,218)</u></u>	<u><u>1,714</u></u>

9. Capital commitments

The company had no material capital commitments at the financial year-ended 31 July 2025.

10. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

11. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 25 September 2025.